Neurocrine Biosciences (NBIX) Morgan Stanley 24th Annual Global Healthcare Conference summary

Macro trends and innovation

• China-originated innovation is raising the competitive bar and expanding access to early-stage assets, especially in validated biology, prompting a focus on speed and selectivity in R&D and BD strategies.

• Collaborations with Chinese partners can accelerate development, with U.S. companies often completing late-stage development and commercialization.

• China is now integral to the global innovation ecosystem, offering high-quality, cost-effective R&D opportunities without shifting core R&D operations abroad.

AI adoption and operational impact

• AI and machine learning tools, including OpenAI and Anthropic, are broadly used to enhance productivity and workflow efficiency.

• AI adoption has improved data analysis, reduced redundant tasks, and made organizational knowledge more accessible.

• AI is used in medicinal chemistry, clinical development, and trial execution, with KPIs focused on decision speed and cost-effectiveness.

• Near-term AI benefits are focused on productivity, while R&D impact is expected to materialize over the mid to long term.

Policy and pricing environment

• Medicare negotiations under the Inflation Reduction Act will impact pricing, with maximum fair price (MFP) for a key product implemented in 2029 and competitor MFP two years earlier.

• Revenue guidance for a flagship product is $2.825–$2.875 billion for the year, with double-digit market growth and patent protection through 2038.

• Statutory Medicare Part D rebates will increase from 2% to 5% next year, affecting net pricing.

• Revenue is expected to dip in 2029 due to MFP, but growth in other products is anticipated to offset this.